Plasma BNP levels correlated with severity markers in children with hypertrophic cardiomyopathy, showing a positive predictive value of 93% for E/Ea s >10 at a cut-off of 50 pg/ml.
Does B-type natriuretic peptide predict disease severity in children with hypertrophic cardiomyopathy?
In children with hypertrophic cardiomyopathy, BNP levels correlate with non-invasive parameters of disease severity, including measures of raised LV filling pressures, providing a useful assessment tool when symptom evaluation is difficult.
Absolute Event Rate: 0% vs 0%
Background: In adults with hypertrophic cardiomyopathy (HCM), plasma B-type natriuretic peptide (BNP) levels correlate with dyspnoea class and other markers of disease severity. In children with HCM, symptoms are a poor guide to disease severity and no studies have evaluated the clinical utility of BNP testing. Objective: To assess the relation of BNP levels to symptoms and markers of disease severity in children with HCM. Methods: Forty-four consecutive patients with HCM (27 male, age ⩽17 years (median 13.6) underwent assessment of plasma BNP. Clinical evaluation of patients was carried out, including ECG, echocardiography and tissue Doppler imaging. Results: BNP levels correlated with maximal left ventricular (LV) wall thickness ( r s = 0.631, p10 (area under the receiver operator characteristic curve = 0.875 (p<0.001)). Conclusions: BNP levels correlate with non-invasive parameters of disease severity in children with HCM, including measures of raised LV filling pressures. For patients in whom evaluation of symptoms is difficult, BNP may be a useful additional tool in the assessment of disease severity.
Kaski et al. (Mon,) reported a other. Plasma BNP levels correlated with severity markers in children with hypertrophic cardiomyopathy, showing a positive predictive value of 93% for E/Ea s >10 at a cut-off of 50 pg/ml.